跳到正文
原文
MedPage Today·· 3 天前精选AI 评分70

SABCS 上将展示辅助派姆单抗在高风险三阴性乳腺癌患者中的疗效

Can Adjuvant Pembrolizumab Improve Outcomes in Triple-Negative Breast Cancer?

AI 导读

SABCS 上将展示 SWOG-S1418/NRG Oncology BR006 试验结果,该试验评估了辅助派姆单抗在三阴性乳腺癌患者中的作用,特别是对无瘤生存率的影响。

推荐理由

SABCS 上将展示一项 III 期临床试验结果,探讨辅助派姆单抗在高风险三阴性乳腺癌患者中的疗效。

正文

— Data to be presented at SABCS may clarify role of adjuvant immunotherapy in high-risk patients

by Gregory Laub, Senior Director, Video, MedPage Today

November 16, 2026 • 2 min read

In this exclusive MedPage Today video, Rena Callahan, MD, of UCLA Health Santa Clarita Cancer Care in California, previews findings from the phase III SWOG-S1418/NRG Oncology BR006 trial of adjuvant pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC) and residual disease following neoadjuvant chemotherapy, set to be presented at the upcoming San Antonio Breast Cancer Symposium (SABCS).

Callahan discusses the potential implications of treatment, including whether pembrolizumab can improve disease-free survival, which patient subgroups might benefit most, and the importance of balancing efficacy against immune-related toxicities.

Following is a transcript of her remarks:

We've known for a while that neoadjuvant immunotherapy specifically with pembrolizumab improves both pathologic complete response rates as well as event-free survival. But one thing that's never been shown is whether or not adjuvant or postoperative anti-PD-1/PD-L1 is helpful at all. So there have been several theories, maybe the tumor has to be intact. There have been negative studies.

There was one called A-BRAVE in which an anti-PD-L1, avelumab [Bavencio], was used adjuvantly and wasn't helpful. So we all have those patients who have neoadjuvant chemotherapy, have residual disease, and we want to give them something that will ultimately change recurrence rates. And so right now we have capecitabine, which is what we usually do in the rare case of having a BRCA mutation. We'll give olaparib [Lynparza], but this trial will answer the question of whether or not for those high-risk patients, whether or not giving an anti-PD-1 inhibitor, pembrolizumab, will change things, change relapse-free survival.

The patients that were enrolled, I believe, in this trial had residual disease. They didn't have to have a lot of node-positive residual disease. I think it just had to be at least a centimeter or greater, and they did not have to have PD-L1 positivity, but it'll be really interesting to see in the analysis whether any of that makes a difference. So, I'm looking forward to looking at subgroups as well, by PD-L1 status, by nodal burdens.

And of course, safety is incredibly important. Are there going to be endocrinopathies? When we use pembrolizumab, I consent patients that they might end up with disease entities, even diabetes, pneumonitis, adrenal insufficiency, that they'll have for the rest of their lives. So it's important to be able to put these risks of toxicities of treatment in context with the benefit of treatment so the patients can make an informed decision.

来源:MedPage Today · medpagetoday.com